- Home
- BST vs NTLA Comparison
BST vs NTLA Comparison
Compare BST & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BST
- NTLA
- Stock Information
- Founded
- BST 2014
- NTLA 2014
- Country
- BST United States
- NTLA United States
- Employees
- BST N/A
- NTLA N/A
- Industry
- BST Finance Companies
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BST Finance
- NTLA Health Care
- Exchange
- BST Nasdaq
- NTLA Nasdaq
- Market Cap
- BST 1.2B
- NTLA 1.0B
- IPO Year
- BST N/A
- NTLA 2016
- Fundamental
- Price
- BST $33.79
- NTLA $7.30
- Analyst Decision
- BST
- NTLA Buy
- Analyst Count
- BST 0
- NTLA 18
- Target Price
- BST N/A
- NTLA $39.44
- AVG Volume (30 Days)
- BST 134.3K
- NTLA 3.4M
- Earning Date
- BST 01-01-0001
- NTLA 05-08-2025
- Dividend Yield
- BST 8.84%
- NTLA N/A
- EPS Growth
- BST N/A
- NTLA N/A
- EPS
- BST N/A
- NTLA N/A
- Revenue
- BST N/A
- NTLA $57,877,000.00
- Revenue This Year
- BST N/A
- NTLA N/A
- Revenue Next Year
- BST N/A
- NTLA N/A
- P/E Ratio
- BST N/A
- NTLA N/A
- Revenue Growth
- BST N/A
- NTLA 59.55
- 52 Week Low
- BST $31.38
- NTLA $6.50
- 52 Week High
- BST $39.59
- NTLA $28.18
- Technical
- Relative Strength Index (RSI)
- BST 39.71
- NTLA 35.63
- Support Level
- BST $32.75
- NTLA $8.50
- Resistance Level
- BST $35.39
- NTLA $9.38
- Average True Range (ATR)
- BST 0.56
- NTLA 0.63
- MACD
- BST 0.02
- NTLA -0.18
- Stochastic Oscillator
- BST 32.36
- NTLA 23.60
About BST BlackRock Science and Technology Trust of Beneficial Interest
BlackRock Science and Technology Trust is a closed-end management investment company. Its investment objective is to provide income and total return through a combination of current income, current gains, and long-term capital appreciation. It focuses on investing, under a normal market condition in equity securities of science and technology companies.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.